Read Next
Pop Culture
Pro-abortion feminist icon Gloria Steinem has died at 92
Cassy Cooke
·Spotlight Articles
Abortion Pill·By Carole Novielli
'Without guardrails': Abortion pill manufacturer refuses to disclose revenue
According to a response from generic abortion pill manufacturer GenBioPro (GBP) to a U.S. Committee request, abortion pill sales make up 95% of the company's revenue, but it refuses disclose the amount of that revenue.
GBP sells only two drugs — mifepristone and misoprostol — which are the two drugs in the abortion pill regimen.
An August 2026 report — published by the Senate Health, Education, Labor, and Pensions (HELP) Committee and led by Senators Bill Cassidy, Steve Daines, James Lankford, Cindy Hyde-Smith, and Lindsey Graham — was entitled, "Mifepristone Without Guardrails: An Investigation Into How Chemical Abortion Drug Makers Are Putting Mothers and Babies At Risk."
The report noted that GBP:
... refused to provide any revenue information other than initially stating that its “sales of mifepristone account for the majority of its revenue.”
When pressed for more information, GBP subsequently stated that its “sales of mifepristone account for approximately 95% of its revenue.”
GBP refused to provide any information as to how much money it makes from the sale of chemical abortion drugs.
GBP oversees the manufacturing of the first approved generic abortion drug, mifepristone (200mg), as well as the second drug used in the abortion pill regimen, misoprostol. While GBP was founded in 2012, (according to a timeline on its website), the company's abbreviated new drug application for a generic Mifeprex wasn't approved by the FDA until April 11, 2019.
GenBioPro previously admitted it had “captured a significant share of the nationwide market for mifepristone.” Media sources indicated that GBP allegedly supplied roughly two-thirds of U.S. abortion pills in 2023.
In a 2023 lawsuit, GBP acknowledged that “[s]ales of the two drugs are essentially the company’s sole source of product revenue,” adding, "Since 2019, when GenBioPro received approval from FDA to sell generic mifepristone, GenBioPro has marketed and sold more than 850,000 units of the product throughout the United States."
In March, the HELP Committee sent a letter to GBP inquiring about profits from the drug and asking GBP to "[p]lease produce an Excel spreadsheet that includes the cost, revenue, and profit from the sale of mifepristone on a quarterly basis since mifepristone’s date of approval in 2019."
A May 11, 2026, response sent by Arnold and Porter, representing GBP, read: "GBP’s sales of mifepristone account for the majority of its revenue. Providing additional information on GBP’s annual revenue from the sale of mifepristone would disclose commercially sensitive business information."
On April 26, 2026, GBP added:
GBP currently is the sole supplier of generic mifepristone in the United States and, upon information and belief, its sales constitute a majority of the U.S. mifepristone market. GBP’s sales of mifepristone account for the majority of its revenue.
Between FDA approval of the ANDA in 2019 and 2023, GBP sold more than 850,000 units of generic mifepristone throughout the United States.
After the committee pressed further, GBP responded again (June 4, 2026)
GBP’s sales of mifepristone account for approximately 95% of its revenue. Providing additional information on GBP’s annual revenue from the sale of mifepristone would disclose nonpublic, commercially sensitive business information.
As a closely-held private entity, GBP has maintained the confidentiality of its mifepristone revenue information since the launch of GBP’s generic mifepristone in 2019.
While GBP was not specific about revenue, a business profile listed by Moody's on its Cortera website suggests that overall sales for GenBioPro sits at between $10M and $25M.
If these are factual numbers, 95% could translate to between $9.5M and $23.75M for the generic abortion pill maker.
This tracks with what Danco Laboratories, (the original manufacturer) told the Committee, namely that they generated nearly $20 million annually in past years from selling Mifeprex alone.
If you add the fact that today, some abortion industry insiders have pivoted to an unapproved one-drug regimen of misoprostol only, it is possible that GBP could be profiting even more than this from abortion.
In its response to the HELP Committee, GBP did not publicly disclose the country of origin where abortion drugs are produced. Reports have indicated concerns over factories making generic drugs generally, but GBP assured Senators, "The facilities manufacturing mifepristone tablets for GenBioPro, Inc. have undergone FDA inspections and remain approved by the FDA for manufacturing."
However, GBP went on to claim it monitors "inspection results from its contract facilities only if the inspection results directly pertain to the manufacturing of GBP’s products."
Overall, abortion by pill is on the increase due in part to the removal of an in-person dispensing requirement by the Food and Drug Administration (FDA), and later, the move to mail-order and pharmacy dispensing under the Biden administration.
Predictions show market increases will continue to rise over the next several years, from $2.1B to nearly $3.7B.
Abortion pill manufacturers are obligated to ensure the FDA's REMS safety rules are followed by prescribers and pharmacies dispensing the drug, yet as Live Action News has documented multiple times, this does not appear to be taking place.
In its letter to the HELP Committee, GBP wrote:
GBP has not had cause to decertify any certified prescriber or certified pharmacy since the launch of GBP’s generic mifepristone in 2019.
GBP’s audits of certified pharmacies have not identified noncompliance with the REMS certification requirements that could not be resolved through corrective actions.
Likewise, GBP has not identified noncompliance with the REMS certification requirements among certified prescribers.
Live Action News identified abortion pill providers and referral organizations clearly advertising use of the drug outside REMS requirements.
For example, Planned Parenthood, which is linked on the GBP website, offers to sell abortion drugs "just in case" a pregnancy occurs, which appears to be outside the FDA's REMS.
GBP told the committee that "any information on the linked site is solely subject to the control of the organization operating the site. GBP thus affirmatively disclaims any control or endorsement of the content of those sites."
GBP went on to write:
GBP complies with its obligations under the REMS. If an actual or suspected instance of prescriber non-compliance were brought to GBP’s attention, GBP would investigate and respond appropriately, including by decertifying the prescriber if the prescriber will not comply with the REMS certification requirements.
Just as the Committee pointed out in its correspondence with Danco, failing to decertify prescribers who are out of compliance with the REMS for Mifepristone Program potentially places "profits above the health and safety of women and children."
Both the highly secretive abortion pill manufacturer Danco Laboratories and GenBioPro were seeded with millions in investment dollars from the pro-abortion David and Lucile Packard Foundation. Other GBP investors include:
ReproHub, led by Christine Charbonneau, whose website claimed she "co-founded Planned Parenthood Online; and co-founded and served as Board Chair of Afaxys." The organization issued a $3.7M grant to GBP in 2024.
Cumming Foundation, whose VP has served on the board of Planned Parenthood, invested $1M/2023.
The Marguerite Casey Foundation shows expenditure grants of $800K (2023, 2024, 2022) to fund clinical trials related to mifepristone.
The San Francisco-based Parsemus Foundation has granted GenBioPro loan dollars ($1.4M/2020, $500K/ 2020, $275K/2018, and $320K/2017) for, as they put it, “operations related to Family Planning.” The Parsemus Foundation was founded by Elaine Lissner in 2005 “to support further research on male contraceptives,” the foundation’s website states.
Soros Economic Fund lists $3M given to GBP under “Other Asset Schedule” in 2023 and 2024.
Asked by the Washington Free Beacon whether the Packard Foundation stands to make a profit if the company increases in value, Packard pointed the Beacon to an online statement which acknowledged that the foundation "take[s] risks in pursuit of impact while seeking overall return of principal" so it "can recycle capital to maximize impacts over the long-term."
GenBioPro is located in Nevada inside commercial office suites located at 3651 Lindell Rd (Ste D1041) in Las Vegas. A label for misoprostol published at Daily Med confirms that address, while GBP's mifepristone label lists only a post office box.
A filing in 2011 with the Nevada Secretary of State shows a registered agent of CSC Services of Nevada, Inc. Filings have listed Robert Armknecht and S. Rizzo as Treasurer, and T. Leonard as Secretary and Director. In addition, BizaPedia shows corporate records filed in Arizona naming Joseph Sinkule as serving on the company's 2011 Board of Directors.
GBP's CEO was Edward Jacobs, according to D&B and LinkedIn, and Mary Fjerstad was listed as Senior Director of Medical Affairs. Thomas Leonard declared himself as the Chief Executive Officer of GBP in a 2021 legal document, citing his duties as "tracking GBP's sales and revenue" and acknowledging that the company's financials were "a closely-held secret."
More currently, GenBioPro’s president, Evan Masingill, has been referred to as the CEO. Masingill was one of the first board members to join the abortion facility Desert Star Institute for Family Planning (DSIFFP) in 2017. DSIFFP was founded by abortionist DeShawn Taylor, described as a senior medical director and consultant for GenBioPro and one of Planned Parenthood’s former abortionists recorded in undercover video by the Center for Medical Progress.
Live Action News is pro-life news and commentary from a pro-life perspective.
Our work is possible because of our donors. Please consider giving to further our work of changing hearts and minds on issues of life and human dignity.
Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.
Guest Articles: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated (see our Open License Agreement). Thank you for your interest in Live Action News!
Cassy Cooke
·
Analysis
Nancy Flanders
·
Abortion Pill
Bridget Sielicki
·
Abortion Pill
Nancy Flanders
·
Abortion Pill
Carole Novielli
·
Abortion Pill
Nancy Flanders
·Abortion Pill
Carole Novielli
·
Abortion Pill
Carole Novielli
·
Abortion Pill
Carole Novielli
·
Analysis
Carole Novielli
·
Analysis
Carole Novielli
·Abortion Pill·By Carole Novielli
'Without guardrails': Abortion pill manufacturer refuses to disclose revenue
According to a response from generic abortion pill manufacturer GenBioPro (GBP) to a U.S. Committee request, abortion pill sales make up 95% of the company's revenue, but it refuses disclose the amount of that revenue.
GBP sells only two drugs — mifepristone and misoprostol — which are the two drugs in the abortion pill regimen.
An August 2026 report — published by the Senate Health, Education, Labor, and Pensions (HELP) Committee and led by Senators Bill Cassidy, Steve Daines, James Lankford, Cindy Hyde-Smith, and Lindsey Graham — was entitled, "Mifepristone Without Guardrails: An Investigation Into How Chemical Abortion Drug Makers Are Putting Mothers and Babies At Risk."
The report noted that GBP:
... refused to provide any revenue information other than initially stating that its “sales of mifepristone account for the majority of its revenue.”
When pressed for more information, GBP subsequently stated that its “sales of mifepristone account for approximately 95% of its revenue.”
GBP refused to provide any information as to how much money it makes from the sale of chemical abortion drugs.
GBP oversees the manufacturing of the first approved generic abortion drug, mifepristone (200mg), as well as the second drug used in the abortion pill regimen, misoprostol. While GBP was founded in 2012, (according to a timeline on its website), the company's abbreviated new drug application for a generic Mifeprex wasn't approved by the FDA until April 11, 2019.
GenBioPro previously admitted it had “captured a significant share of the nationwide market for mifepristone.” Media sources indicated that GBP allegedly supplied roughly two-thirds of U.S. abortion pills in 2023.
In a 2023 lawsuit, GBP acknowledged that “[s]ales of the two drugs are essentially the company’s sole source of product revenue,” adding, "Since 2019, when GenBioPro received approval from FDA to sell generic mifepristone, GenBioPro has marketed and sold more than 850,000 units of the product throughout the United States."
In March, the HELP Committee sent a letter to GBP inquiring about profits from the drug and asking GBP to "[p]lease produce an Excel spreadsheet that includes the cost, revenue, and profit from the sale of mifepristone on a quarterly basis since mifepristone’s date of approval in 2019."
A May 11, 2026, response sent by Arnold and Porter, representing GBP, read: "GBP’s sales of mifepristone account for the majority of its revenue. Providing additional information on GBP’s annual revenue from the sale of mifepristone would disclose commercially sensitive business information."
On April 26, 2026, GBP added:
GBP currently is the sole supplier of generic mifepristone in the United States and, upon information and belief, its sales constitute a majority of the U.S. mifepristone market. GBP’s sales of mifepristone account for the majority of its revenue.
Between FDA approval of the ANDA in 2019 and 2023, GBP sold more than 850,000 units of generic mifepristone throughout the United States.
After the committee pressed further, GBP responded again (June 4, 2026)
GBP’s sales of mifepristone account for approximately 95% of its revenue. Providing additional information on GBP’s annual revenue from the sale of mifepristone would disclose nonpublic, commercially sensitive business information.
As a closely-held private entity, GBP has maintained the confidentiality of its mifepristone revenue information since the launch of GBP’s generic mifepristone in 2019.
While GBP was not specific about revenue, a business profile listed by Moody's on its Cortera website suggests that overall sales for GenBioPro sits at between $10M and $25M.
If these are factual numbers, 95% could translate to between $9.5M and $23.75M for the generic abortion pill maker.
This tracks with what Danco Laboratories, (the original manufacturer) told the Committee, namely that they generated nearly $20 million annually in past years from selling Mifeprex alone.
If you add the fact that today, some abortion industry insiders have pivoted to an unapproved one-drug regimen of misoprostol only, it is possible that GBP could be profiting even more than this from abortion.
In its response to the HELP Committee, GBP did not publicly disclose the country of origin where abortion drugs are produced. Reports have indicated concerns over factories making generic drugs generally, but GBP assured Senators, "The facilities manufacturing mifepristone tablets for GenBioPro, Inc. have undergone FDA inspections and remain approved by the FDA for manufacturing."
However, GBP went on to claim it monitors "inspection results from its contract facilities only if the inspection results directly pertain to the manufacturing of GBP’s products."
Overall, abortion by pill is on the increase due in part to the removal of an in-person dispensing requirement by the Food and Drug Administration (FDA), and later, the move to mail-order and pharmacy dispensing under the Biden administration.
Predictions show market increases will continue to rise over the next several years, from $2.1B to nearly $3.7B.
Abortion pill manufacturers are obligated to ensure the FDA's REMS safety rules are followed by prescribers and pharmacies dispensing the drug, yet as Live Action News has documented multiple times, this does not appear to be taking place.
In its letter to the HELP Committee, GBP wrote:
GBP has not had cause to decertify any certified prescriber or certified pharmacy since the launch of GBP’s generic mifepristone in 2019.
GBP’s audits of certified pharmacies have not identified noncompliance with the REMS certification requirements that could not be resolved through corrective actions.
Likewise, GBP has not identified noncompliance with the REMS certification requirements among certified prescribers.
Live Action News identified abortion pill providers and referral organizations clearly advertising use of the drug outside REMS requirements.
For example, Planned Parenthood, which is linked on the GBP website, offers to sell abortion drugs "just in case" a pregnancy occurs, which appears to be outside the FDA's REMS.
GBP told the committee that "any information on the linked site is solely subject to the control of the organization operating the site. GBP thus affirmatively disclaims any control or endorsement of the content of those sites."
GBP went on to write:
GBP complies with its obligations under the REMS. If an actual or suspected instance of prescriber non-compliance were brought to GBP’s attention, GBP would investigate and respond appropriately, including by decertifying the prescriber if the prescriber will not comply with the REMS certification requirements.
Just as the Committee pointed out in its correspondence with Danco, failing to decertify prescribers who are out of compliance with the REMS for Mifepristone Program potentially places "profits above the health and safety of women and children."
Both the highly secretive abortion pill manufacturer Danco Laboratories and GenBioPro were seeded with millions in investment dollars from the pro-abortion David and Lucile Packard Foundation. Other GBP investors include:
ReproHub, led by Christine Charbonneau, whose website claimed she "co-founded Planned Parenthood Online; and co-founded and served as Board Chair of Afaxys." The organization issued a $3.7M grant to GBP in 2024.
Cumming Foundation, whose VP has served on the board of Planned Parenthood, invested $1M/2023.
The Marguerite Casey Foundation shows expenditure grants of $800K (2023, 2024, 2022) to fund clinical trials related to mifepristone.
The San Francisco-based Parsemus Foundation has granted GenBioPro loan dollars ($1.4M/2020, $500K/ 2020, $275K/2018, and $320K/2017) for, as they put it, “operations related to Family Planning.” The Parsemus Foundation was founded by Elaine Lissner in 2005 “to support further research on male contraceptives,” the foundation’s website states.
Soros Economic Fund lists $3M given to GBP under “Other Asset Schedule” in 2023 and 2024.
Asked by the Washington Free Beacon whether the Packard Foundation stands to make a profit if the company increases in value, Packard pointed the Beacon to an online statement which acknowledged that the foundation "take[s] risks in pursuit of impact while seeking overall return of principal" so it "can recycle capital to maximize impacts over the long-term."
GenBioPro is located in Nevada inside commercial office suites located at 3651 Lindell Rd (Ste D1041) in Las Vegas. A label for misoprostol published at Daily Med confirms that address, while GBP's mifepristone label lists only a post office box.
A filing in 2011 with the Nevada Secretary of State shows a registered agent of CSC Services of Nevada, Inc. Filings have listed Robert Armknecht and S. Rizzo as Treasurer, and T. Leonard as Secretary and Director. In addition, BizaPedia shows corporate records filed in Arizona naming Joseph Sinkule as serving on the company's 2011 Board of Directors.
GBP's CEO was Edward Jacobs, according to D&B and LinkedIn, and Mary Fjerstad was listed as Senior Director of Medical Affairs. Thomas Leonard declared himself as the Chief Executive Officer of GBP in a 2021 legal document, citing his duties as "tracking GBP's sales and revenue" and acknowledging that the company's financials were "a closely-held secret."
More currently, GenBioPro’s president, Evan Masingill, has been referred to as the CEO. Masingill was one of the first board members to join the abortion facility Desert Star Institute for Family Planning (DSIFFP) in 2017. DSIFFP was founded by abortionist DeShawn Taylor, described as a senior medical director and consultant for GenBioPro and one of Planned Parenthood’s former abortionists recorded in undercover video by the Center for Medical Progress.
Live Action News is pro-life news and commentary from a pro-life perspective.
Our work is possible because of our donors. Please consider giving to further our work of changing hearts and minds on issues of life and human dignity.
Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.
Guest Articles: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated (see our Open License Agreement). Thank you for your interest in Live Action News!
Cassy Cooke
·Analysis
Nancy Flanders
·Abortion Pill
Bridget Sielicki
·Abortion Pill
Nancy Flanders
·Abortion Pill
Carole Novielli
·Abortion Pill
Nancy Flanders
·Abortion Pill
Carole Novielli
·Abortion Pill
Carole Novielli
·Abortion Pill
Carole Novielli
·Analysis
Carole Novielli
·Analysis
Carole Novielli
·